Lansoprazole as a rescue agent in chemoresistant tumors: a phase I/II study in companion animals with spontaneously occurring tumors

<p>Abstract</p> <p>Background</p> <p>The treatment of human cancer has been seriously hampered for decades by resistance to chemotherapeutic drugs. Mechanisms underlying this resistance are far from being entirely known. A very efficient mechanism of tumor resistance to...

Full description

Bibliographic Details
Main Authors: Spugnini Enrico P, Baldi Alfonso, Buglioni Sabrina, Carocci Francesca, Milesi de Bazzichini Giulia, Betti Gianluca, Pantaleo Ilaria, Menicagli Francesco, Citro Gennaro, Fais Stefano
Format: Article
Language:English
Published: BMC 2011-12-01
Series:Journal of Translational Medicine
Subjects:
Online Access:http://www.translational-medicine.com/content/9/1/221
id doaj-745f2b65e82440bb8e01325eba216bf0
record_format Article
spelling doaj-745f2b65e82440bb8e01325eba216bf02020-11-24T21:57:29ZengBMCJournal of Translational Medicine1479-58762011-12-019122110.1186/1479-5876-9-221Lansoprazole as a rescue agent in chemoresistant tumors: a phase I/II study in companion animals with spontaneously occurring tumorsSpugnini Enrico PBaldi AlfonsoBuglioni SabrinaCarocci FrancescaMilesi de Bazzichini GiuliaBetti GianlucaPantaleo IlariaMenicagli FrancescoCitro GennaroFais Stefano<p>Abstract</p> <p>Background</p> <p>The treatment of human cancer has been seriously hampered for decades by resistance to chemotherapeutic drugs. Mechanisms underlying this resistance are far from being entirely known. A very efficient mechanism of tumor resistance to drugs is related to the modification of tumour microenvironment through changes in the extracellular and intracellular pH. The acidification of tumor microenvironment depends on proton pumps that actively pump protons outside the cells, mostly to avoid intracellular acidification. In fact, we have shown in pre-clinical settings as pre-treatment with proton-pumps inhibitors (PPI) increase tumor cell and tumor responsiveness to chemotherapeutics. In this study pet with spontaneously occurring cancer proven refractory to conventional chemotherapy have been recruited in a compassionate study.</p> <p>Methods</p> <p>Thirty-four companion animals (27 dogs and 7 cats) were treated adding to their chemotherapy protocols the pump inhibitor lansoprazole at high dose, as suggested by pre-clinical experiments. Their responses have been compared to those of seventeen pets (10 dogs and 7 cats) whose owners did not pursue any other therapy than continuing the currently ongoing chemotherapy protocols.</p> <p>Results</p> <p>The drug was overall well tolerated, with only four dogs experiencing side effects due to gastric hypochlorhydria consisting with vomiting and or diarrhea. In terms of overall response twenty-three pets out of 34 had partial or complete responses (67.6%) the remaining patients experienced no response or progressive disease however most owners reported improved quality of life in most of the non responders. On the other hand, only three animals in the control group (17%) experienced short lived partial responses (1-3 months duration) while all the others died of progressive disease within two months.</p> <p>Conclusions</p> <p>high dose proton pump inhibitors have been shown to induce reversal of tumor chemoresistance as well as improvement of the quality of life in pets with down staged cancer and in the majority of the treated animals PPI were well tolerated. Further studies are warranted to assess the efficacy of this strategy in patients with advanced cancers in companion animals as well as in humans.</p> http://www.translational-medicine.com/content/9/1/221chemotherapylansoprazolemitoxantronecarboplatinproton pump
collection DOAJ
language English
format Article
sources DOAJ
author Spugnini Enrico P
Baldi Alfonso
Buglioni Sabrina
Carocci Francesca
Milesi de Bazzichini Giulia
Betti Gianluca
Pantaleo Ilaria
Menicagli Francesco
Citro Gennaro
Fais Stefano
spellingShingle Spugnini Enrico P
Baldi Alfonso
Buglioni Sabrina
Carocci Francesca
Milesi de Bazzichini Giulia
Betti Gianluca
Pantaleo Ilaria
Menicagli Francesco
Citro Gennaro
Fais Stefano
Lansoprazole as a rescue agent in chemoresistant tumors: a phase I/II study in companion animals with spontaneously occurring tumors
Journal of Translational Medicine
chemotherapy
lansoprazole
mitoxantrone
carboplatin
proton pump
author_facet Spugnini Enrico P
Baldi Alfonso
Buglioni Sabrina
Carocci Francesca
Milesi de Bazzichini Giulia
Betti Gianluca
Pantaleo Ilaria
Menicagli Francesco
Citro Gennaro
Fais Stefano
author_sort Spugnini Enrico P
title Lansoprazole as a rescue agent in chemoresistant tumors: a phase I/II study in companion animals with spontaneously occurring tumors
title_short Lansoprazole as a rescue agent in chemoresistant tumors: a phase I/II study in companion animals with spontaneously occurring tumors
title_full Lansoprazole as a rescue agent in chemoresistant tumors: a phase I/II study in companion animals with spontaneously occurring tumors
title_fullStr Lansoprazole as a rescue agent in chemoresistant tumors: a phase I/II study in companion animals with spontaneously occurring tumors
title_full_unstemmed Lansoprazole as a rescue agent in chemoresistant tumors: a phase I/II study in companion animals with spontaneously occurring tumors
title_sort lansoprazole as a rescue agent in chemoresistant tumors: a phase i/ii study in companion animals with spontaneously occurring tumors
publisher BMC
series Journal of Translational Medicine
issn 1479-5876
publishDate 2011-12-01
description <p>Abstract</p> <p>Background</p> <p>The treatment of human cancer has been seriously hampered for decades by resistance to chemotherapeutic drugs. Mechanisms underlying this resistance are far from being entirely known. A very efficient mechanism of tumor resistance to drugs is related to the modification of tumour microenvironment through changes in the extracellular and intracellular pH. The acidification of tumor microenvironment depends on proton pumps that actively pump protons outside the cells, mostly to avoid intracellular acidification. In fact, we have shown in pre-clinical settings as pre-treatment with proton-pumps inhibitors (PPI) increase tumor cell and tumor responsiveness to chemotherapeutics. In this study pet with spontaneously occurring cancer proven refractory to conventional chemotherapy have been recruited in a compassionate study.</p> <p>Methods</p> <p>Thirty-four companion animals (27 dogs and 7 cats) were treated adding to their chemotherapy protocols the pump inhibitor lansoprazole at high dose, as suggested by pre-clinical experiments. Their responses have been compared to those of seventeen pets (10 dogs and 7 cats) whose owners did not pursue any other therapy than continuing the currently ongoing chemotherapy protocols.</p> <p>Results</p> <p>The drug was overall well tolerated, with only four dogs experiencing side effects due to gastric hypochlorhydria consisting with vomiting and or diarrhea. In terms of overall response twenty-three pets out of 34 had partial or complete responses (67.6%) the remaining patients experienced no response or progressive disease however most owners reported improved quality of life in most of the non responders. On the other hand, only three animals in the control group (17%) experienced short lived partial responses (1-3 months duration) while all the others died of progressive disease within two months.</p> <p>Conclusions</p> <p>high dose proton pump inhibitors have been shown to induce reversal of tumor chemoresistance as well as improvement of the quality of life in pets with down staged cancer and in the majority of the treated animals PPI were well tolerated. Further studies are warranted to assess the efficacy of this strategy in patients with advanced cancers in companion animals as well as in humans.</p>
topic chemotherapy
lansoprazole
mitoxantrone
carboplatin
proton pump
url http://www.translational-medicine.com/content/9/1/221
work_keys_str_mv AT spugninienricop lansoprazoleasarescueagentinchemoresistanttumorsaphaseiiistudyincompanionanimalswithspontaneouslyoccurringtumors
AT baldialfonso lansoprazoleasarescueagentinchemoresistanttumorsaphaseiiistudyincompanionanimalswithspontaneouslyoccurringtumors
AT buglionisabrina lansoprazoleasarescueagentinchemoresistanttumorsaphaseiiistudyincompanionanimalswithspontaneouslyoccurringtumors
AT caroccifrancesca lansoprazoleasarescueagentinchemoresistanttumorsaphaseiiistudyincompanionanimalswithspontaneouslyoccurringtumors
AT milesidebazzichinigiulia lansoprazoleasarescueagentinchemoresistanttumorsaphaseiiistudyincompanionanimalswithspontaneouslyoccurringtumors
AT bettigianluca lansoprazoleasarescueagentinchemoresistanttumorsaphaseiiistudyincompanionanimalswithspontaneouslyoccurringtumors
AT pantaleoilaria lansoprazoleasarescueagentinchemoresistanttumorsaphaseiiistudyincompanionanimalswithspontaneouslyoccurringtumors
AT menicaglifrancesco lansoprazoleasarescueagentinchemoresistanttumorsaphaseiiistudyincompanionanimalswithspontaneouslyoccurringtumors
AT citrogennaro lansoprazoleasarescueagentinchemoresistanttumorsaphaseiiistudyincompanionanimalswithspontaneouslyoccurringtumors
AT faisstefano lansoprazoleasarescueagentinchemoresistanttumorsaphaseiiistudyincompanionanimalswithspontaneouslyoccurringtumors
_version_ 1725855342641807360